Skip to main content
Sinocelltech Group Limited logo

Sinocelltech Group Limited — Investor Relations & Filings

Ticker · 688520 ISIN · CNE100003ZL3 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 659 across all filing types
Latest filing 2021-01-24 Notice of Dividend Amou…
Country CN China
Listing Shanghai Stock Exchange 688520

About Sinocelltech Group Limited

https://www.sinocelltech.com/

Sinocelltech Group Limited focuses on the research, development, and commercialization of innovative biologics, including monoclonal antibodies, recombinant proteins, and vaccine candidates. The company's product pipeline addresses therapeutic areas such as oncology, autoimmune disorders, hematology, and infectious diseases. Key offerings include recombinant human coagulation factor VIII for hemophilia A and a range of biosimilars. Sinocelltech leverages an integrated technology platform encompassing early-stage discovery through to large-scale industrial production. This infrastructure supports the development of high-quality biological medicines aimed at addressing unmet medical needs through advanced protein engineering and cell line development.

Recent filings

Filing Released Lang Actions
2021-2023年分红回报规划
Notice of Dividend Amount Classification · 95% confidence The document is a detailed plan outlining the company's shareholder dividend return policy for the next three years (2021-2023). It discusses principles, conditions, procedures, and mechanisms for profit distribution and cash dividends. It references regulatory guidelines from the China Securities Regulatory Commission and the company's articles of association. The document is not a financial report, earnings release, or audit report, nor is it a brief announcement or a presentation. It is a formal policy document issued by the board regarding dividend distribution planning. This fits best under the category of Notice of Dividend Amount (DIV), as it relates to dividend policy and shareholder returns over a defined period.
2021-01-24 Chinese
第一届监事会第十四次会议决议公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement of resolutions passed at the 14th meeting of the first Supervisory Board of Beijing Shenzhou Cell Biotechnology Group Co., Ltd. The content focuses on approval of a private placement of A shares, including the issuance plan, pricing, number of shares, lock-up periods, use of proceeds, and related party transactions. It also mentions the need for shareholder approval for these resolutions. The document is a formal meeting resolution announcement related to capital raising and share issuance, not the actual issuance report or financial statements. It is not a full annual or interim report, nor an earnings release or audit report. The document is a formal board/management meeting resolution announcement concerning capital raising activities, which fits best under Capital/Financing Update (CAP). The length and detail confirm it is not a brief announcement or a simple report publication notice. Therefore, the classification is CAP with high confidence.
2021-01-24 Chinese
关于变更公司注册资本、公司类型、修订《公司章程》并办理工商变更登记的公告
Governance Information Classification · 95% confidence The document is a detailed announcement from Beijing Shenzhou Cell Biotechnology Group Co., Ltd. regarding changes to the company's registered capital, company type, and amendments to the Articles of Association. It includes extensive legal and regulatory references, detailed descriptions of shareholder rights, board responsibilities, and corporate governance rules. The content focuses on corporate governance structure, shareholder meeting procedures, and company bylaws revisions rather than financial results or audit opinions. There is no indication that this is an annual report, earnings release, or audit report. The document is not a brief announcement but a substantive governance-related filing. Therefore, it fits best under Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices.
2021-01-24 Chinese
关于向特定对象发行A股股票预案披露的提示性公告
Capital/Financing Update Classification · 95% confidence The document is a short announcement (589 characters) regarding the company's 2021 plan to issue A shares to specific investors. It mentions that the proposal and related documents have been disclosed on the stock exchange website and clarifies that this announcement does not represent approval or completion of the issuance. The content focuses on informing investors about the planned capital raising activity rather than providing detailed financial data or the actual issuance. Therefore, this fits the category of a Capital/Financing Update (CAP) rather than a full report or regulatory filing. The document is not a report publication announcement since it does not state that a report is attached or available for download, but rather it is a disclosure of a financing plan.
2021-01-24 Chinese
关于召开2021年第一次临时股东大会的通知
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a detailed notice about convening the 2021 first extraordinary general meeting (临时股东大会) of Beijing Shenzhou Cell Biotechnology Group Co., Ltd. It includes information about the meeting date, voting methods, agenda items, shareholder registration, and proxy voting instructions. The content focuses on the announcement and procedural details of the shareholders' meeting rather than the meeting materials or results. There is no financial data or report content, nor is it a transcript or voting result announcement. The document is a formal meeting notice, which fits the category of Proxy Solicitation & Information Statement (PSI), as it provides information to shareholders to solicit their participation and votes for the meeting.
2021-01-24 Chinese
独立董事关于第一届董事会第十六次会议相关事项的独立意见
Capital/Financing Update Classification · 95% confidence The document is an independent opinion report from independent directors regarding the company's proposal for a specific issuance of A shares to particular investors in 2021. It discusses compliance with laws and regulations, fairness to shareholders, and approval to submit the proposal to the shareholders' meeting. The content focuses on the issuance plan, related agreements, use of raised funds, and associated transactions. This is a detailed report related to capital raising activities, specifically a targeted share issuance. It is not a full annual or interim report, nor an announcement of voting results or a proxy statement. The document length is under 5,000 characters, but it contains substantive independent opinions on the issuance plan, not merely an announcement of a report. Therefore, it fits best under Capital/Financing Update (CAP), which covers updates on company fundraising and capital structure changes.
2021-01-24 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.